Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement

Thrombosis and Haemostasis

Volumn 75, Issue 3, 1996, Pages 407-411

  Cofrancesco, E ^a   Cortellaro, M ^a,c   Leonardi, P ^a   Corradi, A ^b   Ravasi, F ^b   Bertocchi, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Ctro Ric Clin Farmacologica T   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; DESULFATOHIRUDIN; FIBRIN DEGRADATION PRODUCT; HEPARIN; LEPIRUDIN; PROTHROMBIN; THROMBIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TOTAL HIP PROSTHESIS;

EID: 0029875177     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650287     Document Type: Article

References (24)

1. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. Jama 1994; 271: 1780-5.
2. Markwardt F, Hauptmann J, Nowak G, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 1982; 47: 226-9.
3. Bucha E, Nowak G, Markwardt F. Prevention of experimental coronary thrombosis by hirudin. Folia Haematol 1988; 115: 52-8.
4. Hauptmann J, Bruggener E. Markwardt F Effect of heparin, hirudin and a synthetic thrombm inhibitor on antithrombin III in thrombin-induced disseminated intravasculai coagulation in rats. Haemostasis 1987; 17: 321-8.
5. Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA, Silling-Engelhardt G, Close P. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993; 22: 364-72.
6. Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Büller H, Hoet B, Bichler J, Close P. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. JACC 1993; 22: 1080-8.
7. Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R, Close P. Direct thrombin inhibition with Rec-Hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72: 227-31.
8. Eriksson BI, Kälebo P, Ekman S, Baur M, Bach D, Kerry R, Close P. A dose-finding trial evaluating the efficacy and safety of three different doses of recombinant hirudin, CGP 39393 (™Revasc-Ciba), in patients undergoing total hip replacement. Thromb Haemost 1995; 73: 1108 (A).
9. Wildsmith JAW, McClure JH. Anticoagulant drugs and central nerve blockade. Anaesthesia 1991; 46: 613-4.
10. Education & Debate. Regular review. Risk and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992; 305: 567-74.
11. Schlaeppi JM, Vekemans S, Rink H, Chang JY. Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin-thrombin interaction. Eur J Biochem 1990; 188: 463-70.
12. Dahl OE, Pedersen T, Kierulf P, Westvik A-B, Lund P, Arnesen H, Seljeflot I, Abdelnoor M, Lyberg T. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res 1993; 70: 451-8.
13. Dunn ID, Hui ACW, Triffitt PD, Crozier AEC, Gregg PJ, Sinclair ME, Armstrong AL, Mitchell VE. Plasma D-dimer as a marker for postoperative deep venous thrombosis. Thromb Haemost 1994; 72: 663-5.
14. Hoek JA, Nurmohamed MT, ten Cate JW, Büller HR, Knipscheer HC, Hamelynck KJ, Marti RK, Sturk A. Thrombin-antithrombin III complexes in the prediction of deep vein thrombosis following total hip replacement. Thromb Haemost 1989; 62: 1050-2.
15. Sorensen JV, Lassen MR, Borris LC, Rahr HB, Jensen HP, Hoppensteadt D, Walenga JA, Fareed J. Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low-molecular-weight heparin. Blood Coagul Fibrinol 1992; 3: 55-9.
16. Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS. Chesebro JH. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994; 90: 2671-8.
17. Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-8.
18. Schiele F, Vuillemenot A, Kramarz Ph, Kieffer Y, Soria J, Soria C, Camez A, Mirshahi MC, Bassand JP. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 558-62.
19. The DVTENOX Study Group. Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. Thromb Haemost 1993; 70: 909-14.
20. Boneu B, Bes G, Pelzer H, Sié P, Boccalon H. D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2; diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991; 65: 28-32.
21. Estivals M, Pelzer M. Sié P. Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1+2, tnrombin-antithrombin III complexes and D-Dimers in acute deep vein thrombosis: effects of heparin treatment. Brit J Haematol 1991; 78: 421-4.
22. Boisclair MD, Lane DA, Wilde JT, Ireland H, Preston FE, Ofosu FA. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-Dimer and fibrinogen/fibrin fragment E antigen. Brit J Haematol 1990; 74: 471-9.
23. 1+2. Thromb Haemost 1993; 70: 253-8.
24. Green D. Prevention of thromboembolism after spinal cord injury. Sem Thromb Hemost 1991; 17: 347-50.